Determination of Oral Dosage and Pharmacokinetic Analysis of Flecainide in Horses

To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its plasma concentration and PR, QRS and QT intervals in equine electrocardiograms (ECG) were investigated. Six healthy horses were administered...

Full description

Saved in:
Bibliographic Details
Published inJournal of Veterinary Medical Science Vol. 63; no. 5; pp. 511 - 514
Main Authors OHMURA, Hajime, HIRAGA, Atsushi, AIDA, Hiroko, TAKAHASHI, Toshiyuki, NUKADA, Toshio
Format Journal Article
LanguageEnglish
Published Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 01.05.2001
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its plasma concentration and PR, QRS and QT intervals in equine electrocardiograms (ECG) were investigated. Six healthy horses were administered a randomly ordered dose of 4 or 6 mg/kg of flecainide acetate. The ECG was monitored (heart rate (HR), PR, QRS, and QT intervals) and blood was taken at timed intervals to measure the plasma flecainide concentrations pre- and post-administration. The maximum plasma concentration reached 1014 ± 285 (SD) ng/ml in 45 ± 13 min and 1301 ± 400 ng/m l in 60 ± 37 min for doses of 4 and 6 mg/kg flecainide, respectively. From the pharmacokinetic analysis, clearance rates were 14.6 ± 6.4 and 11.7 ± 5.2 ml/kg/min and terminal elimination half-lives were 228 ± 53 and 304 ± 87 min. The QRS and QT intervals increased significantly for both doses following administration, though HR and PR intervals did not change. Plasma flecainide concentrations were significantly correlated with QRS (r=0.935, P<0.001) and QT intervals (r=0.753, P<0.001). In conclusion, plasma concentrations of flecainide for treating equine atrial fibrillation were obtained by oral administration of 4 and 6 mg/kg, and the drug was rapidly eliminated from plasma in horses.
AbstractList To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its plasma concentration and PR, QRS and QT intervals in equine electrocardiograms (ECG) were investigated. Six healthy horses were administered a randomly ordered dose of 4 or 6 mg/kg of flecainide acetate. The ECG was monitored (heart rate (HR), PR, QRS, and QT intervals) and blood was taken at timed intervals to measure the plasma flecainide concentrations pre- and post-administration. The maximum plasma concentration reached 1014 ± 285 (SD) ng/ml in 45 ± 13 min and 1301 ± 400 ng/m l in 60 ± 37 min for doses of 4 and 6 mg/kg flecainide, respectively. From the pharmacokinetic analysis, clearance rates were 14.6 ± 6.4 and 11.7 ± 5.2 ml/kg/min and terminal elimination half-lives were 228 ± 53 and 304 ± 87 min. The QRS and QT intervals increased significantly for both doses following administration, though HR and PR intervals did not change. Plasma flecainide concentrations were significantly correlated with QRS (r=0.935, P<0.001) and QT intervals (r=0.753, P<0.001). In conclusion, plasma concentrations of flecainide for treating equine atrial fibrillation were obtained by oral administration of 4 and 6 mg/kg, and the drug was rapidly eliminated from plasma in horses.
To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its plasma concentration and PR, QRS and QT intervals in equine electrocardiograms (ECG) were investigated. Six healthy horses were administered a randomly ordered dose of 4 or 6 mg/kg of flecainide acetate. The ECG was monitored (heart rate (HR), PR, QRS, and QT intervals) and blood was taken at timed intervals to measure the plasma flecainide concentrations pre- and post-administration. The maximum plasma concentration reached 1014+/-285 (SD) ng/m/ in 45+/-13 min and 1301+/-400 ng/ m/l in 60+/-37 min for doses of 4 and 6 mg/kg flecainide, respectively. From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min. The QRS and QT intervals increased significantly for both doses following administration, though HR and PR intervals did not change. Plasma flecainide concentrations were significantly correlated with QRS (r=0.935, P&lt;0.001) and QT intervals (r=0.753, P&lt;0.001). In conclusion, plasma concentrations of flecainide for treating equine atrial fibrillation were obtained by oral administration of 4 and 6 mg/kg, and the drug was rapidly eliminated from plasma in horses.
To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its plasma concentration and PR, QRS and QT intervals in equine electrocardiograms (ECG) were investigated. Six healthy horses were administered a randomly ordered dose of 4 or 6 mg/kg of flecainide acetate. The ECG was monitored (heart rate (HR), PR, QRS, and QT intervals) and blood was taken at timed intervals to measure the plasma flecainide concentrations pre- and post-administration. The maximum plasma concentration reached 1014+/-285 (SD) ng/m/ in 45+/-13 min and 1301+/-400 ng/ m/l in 60+/-37 min for doses of 4 and 6 mg/kg flecainide, respectively. From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min. The QRS and QT intervals increased significantly for both doses following administration, though HR and PR intervals did not change. Plasma flecainide concentrations were significantly correlated with QRS (r=0.935, P<0.001) and QT intervals (r=0.753, P<0.001). In conclusion, plasma concentrations of flecainide for treating equine atrial fibrillation were obtained by oral administration of 4 and 6 mg/kg, and the drug was rapidly eliminated from plasma in horses.
Author AIDA, Hiroko
NUKADA, Toshio
OHMURA, Hajime
TAKAHASHI, Toshiyuki
HIRAGA, Atsushi
Author_xml – sequence: 1
  fullname: OHMURA, Hajime
  organization: Equine Science Division, Hidaka Yearling Training Farm of Japan Racing Association (JRA)
– sequence: 2
  fullname: HIRAGA, Atsushi
  organization: Equine Science Division, Hidaka Yearling Training Farm of Japan Racing Association (JRA)
– sequence: 3
  fullname: AIDA, Hiroko
  organization: Equine Science Division, Hidaka Yearling Training Farm of Japan Racing Association (JRA)
– sequence: 4
  fullname: TAKAHASHI, Toshiyuki
  organization: Equine Research Institute of JRA
– sequence: 5
  fullname: NUKADA, Toshio
  organization: Joban Branch Equine Research Institute of JRA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11411495$$D View this record in MEDLINE/PubMed
BookMark eNpdkEtLAzEURoNUtD5W7mVAcCNT85pMs7O0vkBQQdchzdxo6kxSk6ngvzelRUG43G9xDx_cc4AGPnhA6ITgEaGSXi6-ujQSbFQRsoOGhPG6rDmTAzTEkoiyphXeRwcpLTCmhAu5h_YJ4XlkNUTPM-ghds7r3gVfBFs8Rt0Ws5D0GxTaN8XTu46dNuHDeeidKSZet9_JpTV704LRzrsGCueLuxATpCO0a3Wb4Hibh-j15vplelc-PN7eTycPpRGU9aVthNVAZC0tBWzrmpOctTFzOWaV4A2lDAyzBkTFsdVzTKwUXHJOK1PNKTtE55veZQyfK0i96lwy0LbaQ1glVWPJKiZEBs_-gYuwivmLpLKOsRhzTGSmLjaUiSGlCFYto-t0_FYEq7VntfasBFPZc6ZPt52reQfNH7sVm4GrDbBIfTb5C-iYHbbwV7ZZufP3ZLJwBZ79ACcEkW8
CitedBy_id crossref_primary_10_1016_j_cveq_2016_11_005
crossref_primary_10_1007_s11259_007_0045_0
crossref_primary_10_1136_vr_152_4_114
crossref_primary_10_1111_vec_12251
crossref_primary_10_2460_javma_252_11_1409
crossref_primary_10_1016_j_taap_2003_11_009
crossref_primary_10_2746_0425164044864516
crossref_primary_10_1053_tvjl_2001_0705
crossref_primary_10_1111_j_1939_1676_2006_tb02844_x
Cites_doi 10.1016/0735-1097(90)90326-K
10.1016/0002-9149(84)90501-0
10.1016/0002-9149(84)90497-1
10.1016/0002-9149(89)90253-1
10.1016/0031-6989(86)90115-3
10.1292/jvms.62.711
10.1016/0002-9149(81)90331-3
10.1136/hrt.48.2.140
10.3999/jscpt.27.713
10.1016/0002-9149(92)91079-J
10.1093/eurheartj/14.8.1127
ContentType Journal Article
Copyright 2001 by the Japanese Society of Veterinary Science
Copyright Japan Science and Technology Agency 2001
Copyright_xml – notice: 2001 by the Japanese Society of Veterinary Science
– notice: Copyright Japan Science and Technology Agency 2001
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QR
7U9
8FD
FR3
H94
M7N
P64
7X8
DOI 10.1292/jvms.63.511
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Chemoreception Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
Virology and AIDS Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Veterinary Medicine
EISSN 1347-7439
EndPage 514
ExternalDocumentID 3158533001
10_1292_jvms_63_511
11411495
article_jvms_63_5_63_5_511_article_char_en
Genre Journal Article
GroupedDBID 29L
2WC
53G
5GY
ACGFO
ACIWK
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DIK
DU5
E3Z
EBS
EJD
HYE
JSF
JSH
KQ8
M48
M~E
N5S
OK1
P2P
RJT
RNS
RPM
RYR
RZJ
TKC
TR2
VH1
XSB
B.T
CGR
CUY
CVF
ECM
EIF
NPM
PGMZT
AAYXX
CITATION
7QR
7U9
8FD
FR3
H94
M7N
P64
7X8
ID FETCH-LOGICAL-c623t-fd6fae1979f2e0f77412e07ccb983564d223ec3fce6540fab01f96494425c5b23
ISSN 0916-7250
IngestDate Fri Aug 16 11:24:23 EDT 2024
Thu Oct 10 18:54:24 EDT 2024
Fri Aug 23 00:41:58 EDT 2024
Sat Sep 28 08:40:37 EDT 2024
Wed Apr 05 11:14:13 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c623t-fd6fae1979f2e0f77412e07ccb983564d223ec3fce6540fab01f96494425c5b23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/jvms/63/5/63_5_511/_article/-char/en
PMID 11411495
PQID 1468684019
PQPubID 2028964
PageCount 4
ParticipantIDs proquest_miscellaneous_70935366
proquest_journals_1468684019
crossref_primary_10_1292_jvms_63_511
pubmed_primary_11411495
jstage_primary_article_jvms_63_5_63_5_511_article_char_en
PublicationCentury 2000
PublicationDate 2001-05-01
PublicationDateYYYYMMDD 2001-05-01
PublicationDate_xml – month: 05
  year: 2001
  text: 2001-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Journal of Veterinary Medical Science
PublicationTitleAlternate J. Vet. Med. Sci.
PublicationYear 2001
Publisher JAPANESE SOCIETY OF VETERINARY SCIENCE
Japan Science and Technology Agency
Publisher_xml – name: JAPANESE SOCIETY OF VETERINARY SCIENCE
– name: Japan Science and Technology Agency
References 3. Duff, H.J., Roden, D.M., Maffucci, R.J., Vesper, B.S., Conard, G.J., Higgins, S.B., Oates, J.A., Smith, R.F. and Woosley, R.L. 1981. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am. J. Cardiol. 48: 1133-1140.
4. Hellestrand, K.J., Bexton, R.S., Nathan, A.W., Spurrell, R.A. and Camm, A.J. 1982. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br. Heart J. 48: 140-148.
9. Piovan, D., Padrini, R., Furlanut, M., Moretto, R. and Ferrari, M. 1986. Plasma and tissue levels of flecainide in rats. Pharmacol. Res. Commun. 18: 739-745.
7. Madrid, A.H., Moro, C., Marin-Huerta, E., Mestre, J.L., Novo, L. and Costa, A. 1993. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur. Heart J. 14: 1127-1131.
2. Conard, G.J. and Ober, R.E. 1984. Metabolism of flecainide. Am. J. Cardiol. 53: 41B-51B.
8. Ohmura, H., Nukada, T., Mizuno, Y., Yamaya, Y., Nakayama, T. and Amada, A. 2000. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. J. Vet. Med. Sci. 62: 711-715.
1. Atarashi, H., Saito, H., Onodera, T., Kobayashi, Y., Koh, M., Sasaki, H., Yasutake, M., Hayakawa, H., Shimomura, M. and Morishita, N. 1996. Phase I study of flecainide acetate (E0735) injection. Jpn. J. Clin. Pharmacil. Ther. 27: 713-723 (in Japanese).
5. Kingma, J.H. and Suttorp, M.J. 1992. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am. J. Cardiol. 70: 56A-61A.
10. Suttorp, M.J., Kingma, J.H., Lie, A., Huen, L. and Mast, E.G. 1989. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am. J. Cardiol. 63: 693-696.
6. Kvam, D.C., Banitt, E.H. and Schmid, J.R. 1984. Antiarrhythmic and electrophysiologic actions of flecainide in animal models. Am. J. Cardiol. 53: 22B-25B.
11. Suttorp, M.J., Kingma, J.H., Jessurun, E.R., Lie, A., Huen, L., van Hemel, N.M. and Lie, K.I. 1990. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J. Am. Coll. Cardiol. 16: 1722-1727.
Kvam, D.C., Banitt, E.H. and Schmid (6) 1984; 53
Kingma, J.H. and Suttorp, M.J. (5) 1992; 70
Hellestrand, K.J., Bexton, R.S., Na (4) 1982; 48
Suttorp, M.J., Kingma, J.H., Jessur (11) 1990; 16
Atarashi, H., Saito, H., Onodera, T (1) 1996; 27
8
Piovan, D., Padrini, R., Furlanut (9) 1986; 18
Duff, H.J., Roden, D.M., Maffucci (3) 1981; 48
Suttorp, M.J., Kingma, J.H., Lie, A (10) 1989; 63
Madrid, A.H., Moro, C., Marin-Huert (7) 1993; 14
Conard, G.J. and Ober, R.E. (2) 1984; 53
References_xml – volume: 16
  start-page: 1722
  issn: 0735-1097
  year: 1990
  ident: 11
  publication-title: J. Am. Coll. Cardiol.
  doi: 10.1016/0735-1097(90)90326-K
  contributor:
    fullname: Suttorp, M.J., Kingma, J.H., Jessur
– volume: 53
  start-page: 41B
  issn: 0002-9149
  year: 1984
  ident: 2
  publication-title: Am. J. Cardiol.
  doi: 10.1016/0002-9149(84)90501-0
  contributor:
    fullname: Conard, G.J. and Ober, R.E.
– volume: 53
  start-page: 22B
  issn: 0002-9149
  year: 1984
  ident: 6
  publication-title: Am. J. Cardiol.
  doi: 10.1016/0002-9149(84)90497-1
  contributor:
    fullname: Kvam, D.C., Banitt, E.H. and Schmid
– volume: 63
  start-page: 693
  issn: 0002-9149
  year: 1989
  ident: 10
  publication-title: Am. J. Cardiol.
  doi: 10.1016/0002-9149(89)90253-1
  contributor:
    fullname: Suttorp, M.J., Kingma, J.H., Lie, A
– volume: 18
  start-page: 739
  issue: 8
  year: 1986
  ident: 9
  publication-title: Pharmacol. Res. Commun.
  doi: 10.1016/0031-6989(86)90115-3
  contributor:
    fullname: Piovan, D., Padrini, R., Furlanut
– ident: 8
  doi: 10.1292/jvms.62.711
– volume: 48
  start-page: 1133
  issn: 0002-9149
  year: 1981
  ident: 3
  publication-title: Am. J. Cardiol.
  doi: 10.1016/0002-9149(81)90331-3
  contributor:
    fullname: Duff, H.J., Roden, D.M., Maffucci
– volume: 48
  start-page: 140
  issn: 0007-0769
  year: 1982
  ident: 4
  publication-title: Br. Heart J.
  doi: 10.1136/hrt.48.2.140
  contributor:
    fullname: Hellestrand, K.J., Bexton, R.S., Na
– volume: 27
  start-page: 713
  year: 1996
  ident: 1
  publication-title: Jpn. J. Clin. Pharmacil. Ther.
  doi: 10.3999/jscpt.27.713
  contributor:
    fullname: Atarashi, H., Saito, H., Onodera, T
– volume: 70
  start-page: 56A
  issn: 0002-9149
  year: 1992
  ident: 5
  publication-title: Am. J. Cardiol.
  doi: 10.1016/0002-9149(92)91079-J
  contributor:
    fullname: Kingma, J.H. and Suttorp, M.J.
– volume: 14
  start-page: 1127
  issn: 0195-668X
  year: 1993
  ident: 7
  publication-title: Eur. Heart J.
  doi: 10.1093/eurheartj/14.8.1127
  contributor:
    fullname: Madrid, A.H., Moro, C., Marin-Huert
SSID ssj0021469
Score 1.6991016
Snippet To determine oral dosage and to evaluate the pharmacokinetics in horses of orally administered flecainide, an antiarrhythmic drug, the correlations between its...
SourceID proquest
crossref
pubmed
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 511
SubjectTerms Administration, Oral
Animals
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - blood
Anti-Arrhythmia Agents - pharmacokinetics
Area Under Curve
Electrocardiography - veterinary
equine
Female
flecainide
Flecainide - administration & dosage
Flecainide - blood
Flecainide - pharmacokinetics
Half-Life
Heart Rate - drug effects
Horses - metabolism
Male
oral administration
pharmacokinetics
Random Allocation
Title Determination of Oral Dosage and Pharmacokinetic Analysis of Flecainide in Horses
URI https://www.jstage.jst.go.jp/article/jvms/63/5/63_5_511/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/11411495
https://www.proquest.com/docview/1468684019
https://search.proquest.com/docview/70935366
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Veterinary Medical Science, 2001, Vol.63(5), pp.511-514
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqwQMvCMZX2QA_7A2l1PlwmseIbqRs3cRoUd-ixLUhrdpMazoJ_iD-Tu5i56PAEPCSVvYpTnw_34d9dyHkKPWFLQcusxyFRbV9xa1ECmZ53jxJ-lK4DsdE4fE5j6bu-5k363S-t6KWtkXaE99-m1fyP1yFNuArZsn-A2frm0ID_Af-whU4DNe_4vGwimWpzL4LTLcf5hgsptMATGHqJdiSWJm1XYIEOCbw8xDzsmxIlGMwxy2m6g2OoxN3V-Zgx2jOeo82Gk8vw1KPJYts1aBldBm-K9vDYrPdfMlqgI2Gmjy7zpd5vX8QnoZR-DEalTDKgf7rdpnt7EywJg5Qaw3Q9o2IwpduTgteh2VmaXs7knHLt3UR2p7UwthxfQsdpra0NuIwa5-Hl6LX00L7F5VgB1hidnGz2vS40zNUu4W3zy_ik-nZWTw5nk12e7WiZ-BTOU4f0wTv2CDQynCA0Wnt2IO20TUdzTuYPFAY-U1r3B3L5-4CjP_P8na_prRvJg_IfcNtGmqUPSQdud4n-59qztOxicJ4RD7s4I7miiLuqMYdBRbQn3BHK9whbYM7mq2pxt1jMj05nryNLPNpDkuAvVxYas5VIlngB8qWfQU-BINfX4g0AJOeu3OwOqVwlJAcXAKVpH2mAu4GLqgI4aW284TsrfO1fEaozQM7GXipYt7cdf00FcIXZcJz4MlBKrvkqJq2-EpXYInRc4XZjXF2Y-7EMLtdEugprYnMsmyI9AVo6y7MbARB0iWHFRdis7w36BMPsBISC7rkVd0NwhdP1JK1zLeb2McwAofzLnmqedc8IXMZbj48__OtD8i9ZuUckr3ieitfgJVbpC9LiP0AV_GrlA
link.rule.ids 315,783,787,27936,27937
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Determination+of+Oral+Dosage+and+Pharmacokinetic+Analysis+of+Flecainide+in+Horses&rft.jtitle=Journal+of+veterinary+medical+science&rft.au=OHMURA%2C+Hajime&rft.au=HIRAGA%2C+Atsushi&rft.au=AIDA%2C+Hiroko&rft.au=TAKAHASHI%2C+Toshiyuki&rft.date=2001-05-01&rft.pub=Japan+Science+and+Technology+Agency&rft.issn=0916-7250&rft.eissn=1347-7439&rft.volume=63&rft.issue=5&rft.spage=511&rft_id=info:doi/10.1292%2Fjvms.63.511&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3158533001
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-7250&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-7250&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-7250&client=summon